High value, high uncertainty
Measuring risk in biopharmaceutical research and other industries
Europe’s biopharmaceutical industry faces one of the highest business risks among six key industry sectors, according to a new comparative study.
Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, the study concludes. The study was conducted by Deloitte and commissioned by Janssen. It compares six industry sectors: the biopharmaceutical industry, commercial aircraft manufacturing, the automotive industry, consumer electronics, food manufacturing and generic pharmaceuticals.